Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Duvelisib + unspecified PD-L1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Duvelisib||Copiktra||IPI-145|INK1197||PIK3CD inhibitor 24 PIK3CG inhibitor 8||Copiktra (duvelisib) prevents the activation of the PI3K delta/gamma-mediated signaling pathways, resulting in tumor cell death (PMID: 25258342). Copiktra (duvelisib) is FDA approved for use in adult patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma (FDA.gov)|
|unspecified PD-L1 antibody||Experimental PD-L1 antibody||PD-L1/PD-1 antibody 65|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||oral cavity cancer||not applicable||Duvelisib + unspecified PD-L1 antibody||Preclinical||Actionable||In a preclinical study, treatment with the combination of low-dose Copiktra (duvelisib) and a PD-L1 antibody resulted in increased infiltration of CD8-positive tumor-infiltrating lymphocytes, decreased tumor volume, and improved survival in mice bearing T-cell inflamed murine oral cancer cell-derived tumors, when compared to either agent alone (PMID: 28364000).||28364000|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|